Answers are grounded in this paper and cite their sources.
An update evaluates acromegaly comorbidities, highlighting pharmacologic implications for complications.
We focus on the most relevant acromegaly comorbidities including cardiorespiratory, metabolic, bone, and oncologic complications. Selected complications that may determine pharmacologic choices are also evaluated.
No takes yet. Share an insight, caveat, or question.
Giustina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: